Last reviewed · How we verify
Tegoprazan tablet
At a glance
| Generic name | Tegoprazan tablet |
|---|---|
| Sponsor | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers (PHASE1)
- A Phase I Study of LX22001 for Injection in Healthy Subjects (PHASE1)
- PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects (PHASE1)
- Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (PHASE3)
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers (PHASE1)
- Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegoprazan tablet CI brief — competitive landscape report
- Tegoprazan tablet updates RSS · CI watch RSS
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. portfolio CI